Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

51
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
51
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

152
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

112
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
112
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

188
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
188
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

105
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
105
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

296
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
296

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphocyte Micronucleus Formation Is Driven by Inflammation-Induced Oxidative DNA Damage in Oesophageal Cancer Development.

International journal of cancer·2026
Same author

Managing fatigue with methylphenidate and physical activity during cancer immunotherapy treatment.

Palliative & supportive care·2025
Same author

Evaluation of using a graphic novel Vivian in nursing curriculum from the perspectives of nurse educators: a three-country qualitative study.

BMC palliative care·2025
Same author

Climate and landscape drivers of a mosquito-borne pathogen in an iconic game bird in the eastern and upper midwestern USA.

Scientific reports·2025
Same author

"I don't think service changed, I think people changed": Palliative care delivery in Aotearoa/New Zealand after COVID-19.

Palliative care and social practice·2025
Same author

Investigation into nurses' emotion regulation while causing pain to adult patients during burns dressing changes: a qualitative study.

Burns : journal of the International Society for Burn Injuries·2024
Same journal

Post-extubation pneumothorax following bougie-assisted endotracheal tube exchange.

BMJ case reports·2026
Same journal

Cardiac tamponade secondary to hypothyroidism.

BMJ case reports·2026
Same journal

Unmasking a rare contrast reaction: acute non-cardiogenic pulmonary oedema after iohexol injection.

BMJ case reports·2026
Same journal

Water gonioscopy-assisted transluminaltrabeculotomy.

BMJ case reports·2026
Same journal

<i>Clostridioides difficile</i> osteomyelitis presenting as a Brodie's abscess of the tibia.

BMJ case reports·2026
Same journal

Steroid refractory rapidly progressing organising pneumonia.

BMJ case reports·2026
See all related articles

Related Experiment Video

Updated: May 14, 2025

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models
08:32

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

21.1K

Zuclopenthixol decanoate induced dysphagia.

Olivia Dupere1, Haeun Ji2, Lisa Williams3

  • 1Mersey and West Lancashire Teaching Hospitals NHS Trust, Southport, UK olivia.dupere@doctors.org.uk.

BMJ Case Reports
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

This case report highlights oropharyngeal dysphagia as a potential side effect of zuclopenthixol. Symptoms resolved after discontinuing the antipsychotic medication.

Keywords:
NeurogastroenterologyParenteral / enteral feedingPsychiatry (drugs and medicines)Psychiatry of old ageUnwanted effects / adverse reactions

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.7K
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.4K

Related Experiment Videos

Last Updated: May 14, 2025

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models
08:32

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

Published on: March 1, 2015

21.1K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.7K
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Dysphagia is a recognized adverse effect of various antipsychotics.
  • Oropharyngeal dysphagia is not a formally acknowledged side effect of zuclopenthixol.
  • Antipsychotic medications are commonly used in managing bipolar affective disorder.

Purpose of the Study:

  • To report a case of sudden onset severe oropharyngeal dysphagia in a patient treated with zuclopenthixol decanoate.
  • To explore potential mechanisms underlying dysphagia associated with zuclopenthixol.
  • To raise awareness of dysphagia as a possible adverse effect of zuclopenthixol.

Main Methods:

  • Case report describing a patient with bipolar affective disorder.
  • Clinical observation of dysphagia symptoms.
  • Medication review and discontinuation of zuclopenthixol decanoate.
  • Literature review on antipsychotic-induced dysphagia.

Main Results:

  • The patient presented with sudden severe oropharyngeal dysphagia.
  • Symptoms spontaneously resolved upon discontinuation of zuclopenthixol decanoate.
  • The case suggests a potential link between zuclopenthixol and dysphagia.

Conclusions:

  • Dysphagia may be an underreported adverse effect of zuclopenthixol.
  • Further investigation into the neuropharmacological mechanisms is warranted.
  • Clinicians should consider dysphagia in patients on zuclopenthixol presenting with swallowing difficulties.